You are now leaving helsinn.com

Please click 'Continue to external site' if you want to continue.

Pipeline

We’re working to identify more unmet medical needs and focus our research where it is needed most. Our growing pipeline includes therapies aimed at providing new solutions in cancer care and rare diseases where no options currently exist, with a goal to help lift the burden of cancer for patients.

Cancer Therapeutics

Vepafestinib1

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Solid Tumors with RET Abnormalities

Cancer Supportive Care

Fosnetupitant - Palonosetron

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Pediatric CINV2

Fosnetupitant - Palonosetron IV

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
IV - China - CINV2,3

Anamorelin4

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Global - Cancer Anorexia-Cachexia in NSCLC5 patients

Other

HM04

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Ghrelin Receptor Antagonist - Prader-Willi Syndrome - Open for partnering

HM01

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Ghrelin Receptor Agonist - Partnered

Notes

The safety and efficacy of the agents identified for the investigational uses have not been established: these agents have not been approved for commercial use by any regulatory authority worldwide, except where noted. There is no guarantee that they will receive health authority approval or become commercially available in any country for the uses being investigated.

 

1.Vepafestinib is co-developed by Helsinn Healthcare SA and Taiho Pharmaceutical Co. Ltd.

2.Chemotherapy-Induced Nausea and Vomiting

3.Approved in multiple territories, including USA and EU

4.Approved in Japan

5.Non-Small Cell Lung Cancer